Fredun Pharmaceuticals Adjusts Valuation Score Amid Strong Financial Performance and Growth

Fredun Pharmaceuticals has recently undergone an evaluation adjustment, reflecting a revision in its score. This change is primarily attributed to a shift in the valuation grade, which has transitioned from attractive to very attractive.
Key financial metrics for Fredun Pharmaceuticals indicate a PE ratio of 18.60 and a price-to-book value of 2.88. The company demonstrates a solid enterprise value to EBITDA ratio of 9.27 and an EV to EBIT ratio of 10.14. Additionally, the PEG ratio stands at 0.70, suggesting a favorable growth outlook relative to its valuation. The dividend yield is modest at 0.09%, while the return on capital employed (ROCE) and return on equity (ROE) are reported at 15.61% and 15.47%, respectively.

In terms of market performance, Fredun Pharmaceuticals has shown a net sales growth rate of 27.60% annually, with operating profit increasing at 35.06%. The company has consistently reported positive results over the last four quarters, with net sales reaching a peak of Rs 167.41 crore.

Overall, the adjustment in evaluation reflects the company's strong financial fundamentals and market position within the pharmaceuticals and biotechnology industry.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.